[SMC] First characterization of congenital myasthenic syndrome type 5 in North Africa

[RSS-Bot]

Mol Biol Rep. 2021 Oct;48(10):6999-7006. doi: 10.1007/s11033-021-06530-7. Epub 2021 Sep 22.

ABSTRACT

BACKGROUND: Congenital myasthenic syndromes (CMS) are associated with defects in the structure and the function of neuromuscular junctions. These rare disorders can result from mutations in the collagenic tail of endplate acetylcholinesterase (COLQ) essentially associated with autosomal recessive inheritance. With the lowered cost of genetic testing and increased access to next-generation sequencing, many mutations have been reported to date.

METHODS AND RESULTS: In this study we identified the first COLQ homozygous mutation c.1193T>A in the North African population. This study outlines the genetic and phenotypic features of a CMS patient in a Moroccan family. It also describes a novel COLQ missense mutation associated with CMS-5.

CONCLUSION: COLQ mutations are probably underdiagnosed in these North African populations, this is an issue as CMS-5 may be treated with ephedrine, and albuterol. Indeed, patients can seriously benefit and even recover after the treatment that should be planned according to genetic tests and clinical findings.

PMID:34553317 | DOI:10.1007/s11033-021-06530-7


Source: https://pubmed.ncbi.nlm.nih.gov/3455331 ... 0&v=2.17.5